2025 San Antonio Breast Cancer Symposium: Evolving First-Line Approaches in Metastatic HER2+ Breast Cancer

from Medical News Podcast · host PeerDirect Publishing

Drs. Isaacs and Traina discuss DESTINY-Breast09, where first‑line T‑DXd + pertuzumab clearly outperforms the CLEOPATRA regimen in progression-free survival for metastatic HER2+ breast cancer. They focus on the dilemma of when to use T‑DXd: earlier, for maximal efficacy, or later, to protect quality of life and manage ILD and cardiac risks.

Episode metadata supplied by the publisher feed · Published Mar 25, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

2025 San Antonio Breast Cancer Symposium: Evolving First-Line Approaches in Metastatic HER2+ Breast Cancer

0:00 11:08

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical News Podcast?

This episode is 11 minutes long.

When was this Medical News Podcast episode published?

This episode was published on March 25, 2026.

Can I download this Medical News Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!